Welcome to BrightVia
We are a consulting firm that transforms clinical evidence into regulatory and strategic value for the pharmaceutical market. Our work is guided by scientific rigor, clarity, and purpose.
We are a consulting firm that transforms clinical evidence into regulatory and strategic value for the pharmaceutical market. Our work is guided by scientific rigor, clarity, and purpose.
BrightVia is a scientific and strategic consulting firm specialized in the comparative evaluation of pharmaceutical products seeking entry into the Brazilian market.
Rigorous scientific methodology in all our analyses and evaluations.
Transforming clinical evidence into actionable strategic insights.
Specialized expertise in Brazilian pharmaceutical regulations.
Our mission is to transform clinical evidence into regulatory and market value, supporting pharmaceutical companies in obtaining a fair pricing position under Brazilian regulations.
We analyze data. We uncover value.
We conduct comparative scientific analyses between the client's product and competitors already registered in Brazil.
We evaluate efficacy and safety using clinical trials, meta-analyses, and real-world data.
We identify differentiating features to support market positioning and pricing decisions.
In the frequent absence of head-to-head trials, particularly in rare diseases where patient populations are small and direct comparative studies are often unfeasible, well-conducted ITCs will be essential.
These statistical analyses, such as network meta-analyses, will be used to compare the new therapy with existing treatments. In such contexts, ITCs represent the best available option to inform decision-making.
The methodological rigor and transparency of these comparisons will be heavily scrutinized.
Identification of comparable medications approved in Brazil.
Selection of relevant scientific and clinical studies for all products analyzed.
Evaluation of efficacy and safety profiles under rigorous methodology.
Creation of publication-ready scientific articles with formal methodology.
A ready-to-publish scientific article, ideal for CMED submission or academic publication.
Exclusive focus on the Brazilian regulated market
Scientific rigor and regulatory alignment
Science, regulation, and market access expertise
Deliverables oriented to impact, clarity, and publication
Let us help you navigate the Brazilian pharmaceutical market with confidence and scientific rigor.